605 related articles for article (PubMed ID: 16447221)
1. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
2. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.
Cejka D; Hayer S; Niederreiter B; Sieghart W; Fuereder T; Zwerina J; Schett G
Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288
[TBL] [Abstract][Full Text] [Related]
4. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.
Kumar S; Votta BJ; Rieman DJ; Badger AM; Gowen M; Lee JC
J Cell Physiol; 2001 Jun; 187(3):294-303. PubMed ID: 11319753
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
[TBL] [Abstract][Full Text] [Related]
6. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis.
Hayer S; Redlich K; Korb A; Hermann S; Smolen J; Schett G
Arthritis Rheum; 2007 Jan; 56(1):79-88. PubMed ID: 17195210
[TBL] [Abstract][Full Text] [Related]
7. The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss.
Böhm C; Hayer S; Kilian A; Zaiss MM; Finger S; Hess A; Engelke K; Kollias G; Krönke G; Zwerina J; Schett G; David JP
J Immunol; 2009 Nov; 183(9):5938-47. PubMed ID: 19828631
[TBL] [Abstract][Full Text] [Related]
8. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
[TBL] [Abstract][Full Text] [Related]
9. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
Medicherla S; Ma JY; Mangadu R; Jiang Y; Zhao JJ; Almirez R; Kerr I; Stebbins EG; O'Young G; Kapoun AM; Luedtke G; Chakravarty S; Dugar S; Genant HK; Protter AA
J Pharmacol Exp Ther; 2006 Jul; 318(1):132-41. PubMed ID: 16597712
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
Binder NB; Puchner A; Niederreiter B; Hayer S; Leiss H; Blüml S; Kreindl R; Smolen JS; Redlich K
Arthritis Rheum; 2013 Mar; 65(3):608-17. PubMed ID: 23280418
[TBL] [Abstract][Full Text] [Related]
11. Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation.
van Lent PL; Grevers L; Lubberts E; de Vries TJ; Nabbe KC; Verbeek S; Oppers B; Sloetjes A; Blom AB; van den Berg WB
Arthritis Rheum; 2006 Dec; 54(12):3868-77. PubMed ID: 17133594
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
[TBL] [Abstract][Full Text] [Related]
13. JNK1 is not essential for TNF-mediated joint disease.
Köller M; Hayer S; Redlich K; Ricci R; David JP; Steiner G; Smolen JS; Wagner EF; Schett G
Arthritis Res Ther; 2005; 7(1):R166-73. PubMed ID: 15642137
[TBL] [Abstract][Full Text] [Related]
14. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis.
Saito H; Kojima T; Takahashi M; Horne WC; Baron R; Amagasa T; Ohya K; Aoki K
Arthritis Rheum; 2007 Apr; 56(4):1164-74. PubMed ID: 17393436
[TBL] [Abstract][Full Text] [Related]
15. Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs.
Nieminen R; Korhonen R; Moilanen T; Clark AR; Moilanen E
Arthritis Rheum; 2010 Jun; 62(6):1650-9. PubMed ID: 20178133
[TBL] [Abstract][Full Text] [Related]
16. TNF-alpha mediates p38 MAP kinase activation and negatively regulates bone formation at the injured growth plate in rats.
Zhou FH; Foster BK; Zhou XF; Cowin AJ; Xian CJ
J Bone Miner Res; 2006 Jul; 21(7):1075-88. PubMed ID: 16813528
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo.
Jimi E; Aoki K; Saito H; D'Acquisto F; May MJ; Nakamura I; Sudo T; Kojima T; Okamoto F; Fukushima H; Okabe K; Ohya K; Ghosh S
Nat Med; 2004 Jun; 10(6):617-24. PubMed ID: 15156202
[TBL] [Abstract][Full Text] [Related]
18. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
Konda VR; Desai A; Darland G; Bland JS; Tripp ML
Arthritis Rheum; 2010 Jun; 62(6):1683-92. PubMed ID: 20201075
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
20. The loss of α2β1 integrin suppresses joint inflammation and cartilage destruction in mouse models of rheumatoid arthritis.
Peters MA; Wendholt D; Strietholt S; Frank S; Pundt N; Korb-Pap A; Joosten LA; van den Berg WB; Kollias G; Eckes B; Pap T
Arthritis Rheum; 2012 May; 64(5):1359-68. PubMed ID: 22083543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
